Current Appointments & Affiliations
Instructor, Medical Center in the Department of Pharmacology and Cancer Biology
·
2025 - Present
Pharmacology & Cancer Biology,
Basic Science Departments
Recent Publications
A phase 1/2a dose-finding study and biomarker assessment of oral lisavanbulin in patients with high-grade glioma or glioblastoma.
Journal Article Cell Rep Med · June 17, 2025 Lisavanbulin is a prodrug of the microtubule-targeting agent avanbulin. Both avanbulin and lisavanbulin have demonstrated significant antitumor activity in several preclinical tumor models including glioblastoma. Previous human studies demonstrated that 48 ... Full text Link to item CiteCharacterization of FGFR Alterations and Activation in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
Journal Article Clin Cancer Res · December 2, 2024 PURPOSE: The Genomic Analysis of High-Risk Non-Muscle-Invasive Bladder Cancer (GARNER) study investigated FGFR alteration (ALT) frequency and the clinical outcome relationship with Bacillus Calmette-GuĂ©rin (BCG) treatment in high-risk non-muscle-invasive b ... Full text Link to item CiteThe Immunogenomic Landscape of Peripheral High-Dose IL-2 Pharmacodynamics in Patients with Metastatic Renal Cell Carcinoma: A Benchmark for Next-Generation IL-2-Based Immunotherapies.
Journal Article J Immunol · July 1, 2024 High-dose (HD) IL-2 was the first immuno-oncology agent approved for treating advanced renal cell carcinoma and metastatic melanoma, but its use was limited because of substantial toxicities. Multiple next-generation IL-2 agents are being developed to impr ... Full text Link to item CiteEducation, Training & Certifications
University of Wisconsin, Madison ·
2002
Ph.D.